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and 38.4% used any type of pharmacotherapy (NRT and/or OPT). A quarter of smokers/ex-smokers used
a combination of aids. NVPs and NRT were the most prevalent types of cessation aids used in all four
countries; however, NRT was more commonly used in Australia relative to NVPs, and in England, NVPs
were more commonly used than NRT. The use of NVPs or NRT was more evenly distributed in Canada
and the US. Conclusions: It appears that many smokers are still trying to quit unassisted, rather than
utilizing cessation aids or other forms of assistance. Of those who did use assistance, NRT and NVPs
were the most common method, which appears to suggest that nicotine substitution is important for
smokers when trying to quit smoking.
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Abstract
Introduction: This study retrospectively describes smoking cessation aids, cessation services, 
and other types of assistance used by current and ex-smokers at their last quit attempt in four 
high-income countries.
Aims and Methods: Data are from the Wave 3 (2020) International Tobacco Control Four Country 
Smoking and Vaping Survey in Australia, Canada, England, and the United States (US). Eligible 
respondents were daily smokers or past-daily recent ex-smokers who made a quit attempt/quit 
smoking in the last 24-months, resulting in 3614 respondents. Self-reported quit aids/assistance 
included: nicotine vaping products (NVPs), nicotine replacement therapy (NRT), other pharmaco-
logical therapies (OPT: varenicline/bupropion/cytisine), tobacco (noncombustible: heated tobacco 
product/smokeless tobacco), cessation services (quitline/counseling/doctor), other cessation sup-
port (e.g., mobile apps/website/pamphlets, etc.), or no aid.
Results: Among all respondents, at last quit attempt, 28.8% used NRT, 28.0% used an NVP, 12.0% 
used OPT, 7.8% used a cessation service, 1.7% used a tobacco product, 16.5% other cessation sup-
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(57.2%) reported using any type of pharmacotherapy (NRT or OPT) and/or an NVP, half-used NRT 
and/or an NVP (49.9%), and 38.4% used any type of pharmacotherapy (NRT and/or OPT). A quarter 
of smokers/ex-smokers used a combination of aids. NVPs and NRT were the most prevalent types 
of cessation aids used in all four countries; however, NRT was more commonly used in Australia 
relative to NVPs, and in England, NVPs were more commonly used than NRT. The use of NVPs or 
NRT was more evenly distributed in Canada and the US.
Conclusions: It appears that many smokers are still trying to quit unassisted, rather than utilizing 
cessation aids or other forms of assistance. Of those who did use assistance, NRT and NVPs were 
the most common method, which appears to suggest that nicotine substitution is important for 
smokers when trying to quit smoking.
Implications: Clinical practice guidelines in a number of countries state that the most effective 
smoking cessation method is a combination of pharmacotherapy and face-to-face behavioral 
support by a health professional. Most quit attempts however are made unassisted, particularly 
without the use of government-approved cessation medications. This study found that about two 
in five daily smokers used approved cessation medications (nicotine replacement therapy (NRT) or 
other approved pharmacotherapies, such as varenicline). Notably, nicotine substitution in the form 
of either NRT and nicotine vaping products (NVPs) were the most common method of cessation 
assistance (used by one in two respondents), but the proportion using NRT and/or NVPs varied 
by country. Few smokers who attempted to quit utilized cessation services such as stop-smoking 
programs/counseling or quitlines, despite that these types of support are effective in helping 
smokers manage withdrawals and cravings. Primary healthcare professionals should ask their pa-
tients about smoking and offer them evidence-based treatment, as well as be prepared to provide 
smokers with a referral to trained cessation counselors, particularly when it comes to tailoring 
intensive treatment programs for regular daily smokers. Additionally, healthcare providers should 
be prepared to discuss the use of NVPs, particularly if smokers are seeking advice about NVPs, 
wanting to try/or already using an NVP to quit smoking, have failed repeatedly to quit with other 
cessation methods, and/or if they do not want to give up tobacco/nicotine use completely.
Introduction
Tobacco dependence is a chronic and relapsing condition, and 
smoking cessation is typically preceded by multiple failed quit at-
tempts, particularly among those who have greater nicotine depend-
ence.1,2 Sustained and successful cessation often requires repeated 
interventions and long-term support, and using an aid can double 
the chances of staying quit.1,3,4 Clinical practice guidelines in a 
number of countries state that the most effective smoking cessation 
method is a combination of pharmacotherapy and face-to-face be-
havioral support by a health professional.1,5 However, most quit at-
tempts are made without guideline-based treatments, which results 
in a 90–95% failure rate,1,4 partly owing to smokers depending on 
their own willpower, and/or because they are unaware of effective 
treatments to assist with quitting.1,6
Over the last decade, the tobacco and nicotine product landscape 
has undergone dramatic changes with the emergence of novel and 
alternative products.1,7 The availability of less toxic forms of nico-
tine delivery (e.g., heated tobacco products, e-cigarettes, and snus) 
may represent a new paradigm for smoking cessation by offering 
smokers an opportunity to obtain nicotine in ways that do not re-
quire inhaling tobacco smoke. For example, nicotine vaping prod-
ucts (NVPs, known as e-cigarettes) are potential smoking cessation 
aids that can replace nicotine and provide a behavioral substitution 
for cigarette smoking. In recent years, the use of NVPs for smoking 
cessation has surpassed the use of other government-approved med-
ical therapies in some high-income countries where they are legal and 
regulated, including in the United States (US), England, Canada, and 
some European countries.8–11 Moreover, a recent Cochrane review 
concluded that there is moderate evidence that NVPs with nicotine 
increase quit rates compared to nicotine replacement therapy (NRT) 
and nonnicotine-based vaping products.12 However, NVPs are not 
recommended as a cessation aid in clinical practice guidelines in any 
country, with the exception of England.13,14 Their inclusion has been 
opposed by governments, policy-makers, and medical organiza-
tions,15 fueled by the uncertainty of long-term safety and effective-
ness, the concern that NVPs may weaken tobacco control measures, 
and that NVPs might serve as a gateway to smoking for nonsmoking 
youth and young adults.1,7,16,17 In light of these controversies about 
NVPs, and their absence from clinical practice guidelines, healthcare 
professionals rarely recommend them to smokers.18
Investigation of how NVPs are used by smokers, and whether 
they are being used to support a quit attempt should be a research 
priority. Moreover, exploring other types of cessation assistance is 
warranted, such as advice from a health professional, behavioral 
therapy, quitline services, and web and phone-based interventions, 
which have been found to be useful and effective for assisting 
smokers during a cessation attempt.1 The current study is a retro-
spective and descriptive analysis of self-reported quit aids/assistance 
(pharmacotherapy, NVPs, noncombustible tobacco products, ces-
sation services, and other forms of support) used among a broad 
sample of adult current daily smokers and recent ex-smokers at their 
most recent quit attempt in Australia, Canada, England, and the US.
Methods
The International Tobacco Control Project Four Country Smoking 
and Vaping (ITC 4CV) Survey is a cohort study that consists of par-
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Respondents (adults ≥ 18 years) were recruited by commercial panel 
firms in each country as established cigarette smokers (smoke ≥ monthly, 
and smoked at least 100 cigarettes in their lifetime), recent ex-smokers 
(quit ≤ 2 years), or vapers (vape ≥ weekly). Full details of the ITC 4CV 
Surveys can be found in the Wave 3 (2020) technical report.19
The Wave 3 2020 ITC 4CV Survey was conducted from February 
to June 2020, and included 11 607 respondents, of whom 7298 were 
daily smokers and 1010 were recent ex-smokers at the time of the 
survey. Respondents were eligible for inclusion for the analyses in 
the current study if they were current daily smokers or past-daily 
ex-smokers who self-reported that they had made a quit attempt/quit 
smoking in the last 24 months. This resulted in a sample of 3614 eli-
gible respondents. Respondents’ characteristics are shown in Table 1.
Measures
Self-reported Quit Aids/Assistance
Those who answered that they made a quit attempt (current 
smokers) or quit smoking (ex-smokers) in the last 24 months were 
subsequently asked: “Did you use a vaping product on your last 
(smokers)/current (ex-smokers) quit attempt?” Responses were: 
“yes,” “no,” refused or “don”t know.” Those who had never vaped, 
or answered “no” or “don’t know,” were included as “no.” Those 
who did not answer the question were excluded.
For the use of other aids/assistance (referred to hereafter as 
“quit aids”), respondents were asked: “Which of the following 
forms of help did you receive or use as part of your last (smokers) 
/ current (ex-smokers) quit attempt?” (referred to hereafter as “last 
quit attempt” [LQA]). Respondents could select from the following 
aids (multiple options were allowed to be selected): (1) NRT; (2) 
varenicline (Chantix™ or Champix); (3) bupropion (Zyban or 
Wellbutrin); (4) cytisine; (5) quitline service; (6) stop smoking ser-
vice/behavior counseling; (7) smoking cessation session(s) offered 
by your doctor; (8) mobile apps; (9) cessation website; (10) pamph-
lets or brochures; (11) heated tobacco product (e.g., IQOS); (12) 
smokeless tobacco (snus, chew, or dip); (13) other type of aid not 
mentioned above (open-ended: books, acupuncture, laser therapy, 
hypnosis, support groups, social media, cognitive behavioral 
therapy, meditation/mindfulness, or quit campaign). Mutually ex-
clusive categories were created to distinguish between “exclusive 
use” or “used in combination” (see Table 2).
Statistical Analyses
All estimates are descriptive and were estimated using adjusted re-
gression analyses on weighted data using cross-sectional survey 
weights. A  raking algorithm was used to calibrate the weights on 
smoking status, geographic region, and demographic measures. 
Weighting also adjusted for the oversampling of vapers and younger 
respondents aged 18–24 recruited for the ITC 4CV3 Survey.19
The initial descriptive analyses estimated the prevalence of each 
cessation aid used (yes vs. no) at LQA (not mutually exclusive) among 
the entire study sample (n = 3614). Second, we then explored various 
combined types of aids used among all respondents in the study (yes 
vs. no): (1) any type of other pharmacological therapies (OPT); (2) 
any type of pharmacotherapy (NRT/OPT); (3) any use of NRT and/
or NVP (nicotine replacement); (4) any use of pharmacotherapy and/
or NVPs; (5) any use of a (noncombustible) tobacco product; (6) any 
use of cessation services (quitline, doctor, clinic/counseling); and (7) 
any use of other types of support (mobile apps, cessation website, 
pamphlets/brochures, books, acupuncture, laser therapy, hypnosis, 
support groups, social media, cognitive behavioral therapy, medi-
tation/mindfulness, quit campaign). Third, we then examined the 
prevalence of exclusive use of exclusive use of nicotine and/or an 
OPT among all respondents (n = 3614, yes vs. no) for: (1) pharmaco-
therapy (NRT/OPT only); and any type of pharmacotherapy, and/or 
alternative tobacco/nicotine products (NRT/OPT/NVP/tobacco) to 
see if respondents were substituting their nicotine only (e.g., without 
the use of other forms of support or cessation services). Fourth, we 
investigated the use of cessation aid categories (yes vs. no) by (1) 
country (n  =  3614), and then (2) conditionally among only those 
who used an aid at LQA (n = 2606) for NVP; NRT; OPT, tobacco, 
cessation services; and other support (not mutually exclusive). The 
between-country analysis also included “no aid,” but did not include 
heated tobacco products (HTPs)/smokeless tobacco due to the small 
number of smokers who used them in some countries. Finally, we 
examined aids used alone or in combination (mutually exclusive) or 
no aid (n = 3614).
All analyses controlled for age, sex, country, respondent type (co-
hort vs. replenishment), and smoking status (current daily smoker 
vs. recent ex-smoker). All confidence intervals were computed at the 
95% confidence level. Analyses were conducted using SAS Version 
9.4 (SAS Institute Inc. 2013, Cary, North Carolina, USA).
Results
Quit Aids Used at LQA
Table 2 shows the quit aids used at LQA. Among all smokers/
ex-smokers (N = 3614), 38.6% used no type of aid at all, 28.8% 
used NRT, 28.0% used an NVP, 12.0% used OPT, 7.8% used a ces-
sation service, 1.7% used a noncombustible tobacco product, and 
16.5% used other types of cessation support. Slightly more than half 
of the respondents (57.2%) used pharmacotherapy (NRT/OPT) and/
or an NVP, half used NRT and/or an NVP (49.9%), and 38.4% used 
a form of pharmacotherapy.
When quit aids at LQA were examined to describe use either ex-
clusively or in combination, 13.6%, 12.2%, 5.5%, 4.6%, and 0.8% 
exclusively used an NVP, NRT, OPT, other types of support, or ces-
sation services respectively. Among respondents who did not use 
any type of services or other support, 17.4% used pharmacotherapy 
only and 33.0% used pharmacotherapy, NVP, and/or tobacco only. 
A quarter of respondents used a combination of various forms of as-
sistance (Table 2).
Among those who did use an aid at LQA (n = 2606), 45.8% used 
NRT, 44.3% used an NVP, 19.0% used OPT, 12.4% used cessation 
services, and 26.0% used other types of support (see Figure 1).
Country Differences in Aids Used at LQA
Figure 2 shows the aids used by country and Table 3 shows the 
country post hoc analyses. Using no aid was highest in the US 
(40.2%), followed by Canada (35.1%), England (34.0%), and 
Australia (33.4%), although there was little evidence for statistical 
differences between countries (p = .26).
NVP use differed between countries (p < .0001), with a signifi-
cantly higher percentage of respondents using NVP for quit attempts 
in England (36.7%) relative to the other three countries [Canada 
(26.7%), the US (22.1%), and Australia (21.5%)].
NRT use also differed between countries (p  =  .002), with 
Australian respondents reporting the highest rate of NRT use 
(34.5%), followed by Canada (33.0%), the US (29.5%), and England 
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of NRT use compared to England, and England a higher proportion 
than the US (Figure 2).
The use of OPT differed by country (p = .04), with the US having 
the highest proportion of OPT use (15.5%), followed by Australia 
(14.4%), Canada (11.2%), and England (10.1%). The US had 
a significantly higher proportion of OPT use than both England 
and Canada.
The use of cessation services differed by countries (p < .001). 
England (10.8%) had a significantly higher proportion of respond-
ents who used cessation services compared to Canada (6.4%) and 
the US (5.0%). Australia and England had a significantly higher pro-
portion of the use of cessation services compared to the US, and 
England also had a significantly higher rate than Canada.
Finally, the use of other types of support also differed by country 
(p = .01), where Canada (18.3%), England (18.3%), and Australia 
(17.5%) were all more likely to utilize other types of support than 
the US (11.0%).
Discussion
This study retrospectively describes smoking cessation aids, ces-
sation services, and other types of assistance used by current and 
ex-smokers at their LQA in Australia, Canada, England, and the US. 
Overall, we found that slightly more than one-third of respondents 
did not use any type of aid at LQA, and about two in five respondents 
used approved cessation medications (NRT and/or OPT). Notably, 
nicotine substitution in the form of either NRT and/or NVPs was 
the most common method of cessation assistance (used by one in 
two respondents), but the proportion using NRT or NVPs varied by 
country. Interestingly, it appears that the prevalence of pharmaco-
therapy use (NRT and OPT) for a quit attempt has remained stable 
(about 40%) across the four countries since 2008.20
Few respondents used other forms of services and support. 
For example, about 8% of respondents reported using any type 
of services from their doctor, a cessation clinic/service, and/or a 
quitline, which is disconcerting, considering that counseling from 
healthcare providers and cessation counselors are effective in helping 
smokers learn how to manage withdrawals and cravings.1,21,22 These 
service providers can also suggest the use of medical therapies that 
can further increase a smokers’ chance of quitting.1,4,5 Unfortunately, 
studies have shown that a large proportion of smokers who have had 
a recent physician visit do not receive advice to quit smoking,1,11,18 
and receive a much lower level of systematic identification and sup-
port compared to other chronic conditions.23,24 This lack of guidance 
constitutes a lost opportunity to help smokers, especially since some 
smokers are unaware of the forms of cessation assistance that are 
available, or they do not believe that cessation aids improve the like-
lihood of quitting.1,6 Perhaps most importantly, primary healthcare 
professionals and other specialists should ask their patients about 
smoking and offer them treatment, as well as be prepared to provide 
smokers with a referral to trained cessation counselors, particularly 
when it comes to tailoring intensive treatment programs for regular 
daily smokers who may be highly addicted.1,4,5
While this study did not examine the efficacy of any type of 
cessation aid or other assistance, we found that among those who 
did use an aid at LQA, nearly half used an NVP despite the con-
troversy in many countries in supporting their use. Population evi-
dence regarding the effectiveness of using NVPs to quit smoking is 
mixed; however, there is growing evidence from randomized trials 
and observational studies that NVPs can be helpful in facilitating 
quit smoking attempts, reductions in cigarette consumption, and 
smoking cessation.8,12,25–31 While the evidence of effectiveness for 
cessation has not been found in other studies,25,32,33 it does indi-
cate stronger effects when NVPs are used to quit smoking (vs. use 
for other reasons) when a certain type of device used (e.g., tank-
based system, salt-based e-liquid), and when used more frequently 
(e.g., daily).27,33–37
There were some cross-country differences found in this study. 
For example, England had the highest proportion of respondents 
who used an NVP for cessation compared to the other three coun-
tries. This is not surprising, given that England has the most sup-
portive smoking harm-reduction policies, with several public health 
organizations supporting the use of NVPs for cessation.13,14 Using 
NVPs as cessation support is included in the National Institute 
for Health and Care Excellence guidelines, providing guidance for 
health professionals to give informed advice about the use of NVPs 
Table 1. Respondents’ Characteristics, Unweighted %
Canada United States England Australia Overall sample
n = 1211 n = 706 n = 1108 n = 589 N = 3614
Respondent type Cohort 46.7 59.6 37.4 58.2 48.2
Replenishment 53.3 40.4 62.6 41.8 51.8
Sex Male 43.7 46.2 51.8 46.5 47.1
Female 56.3 53.8 48.2 53.5 52.9
Age group 18–39 52.4 40.7 55.4 18.3 45.5
40+ 47.7 59.4 44.6 81.7 54.5
Education level Low 28.7 32.9 11.6 30.1 24.5
Moderate 44.2 41.9 53.2 41.1 46.0
High 26.7 25.1 33.4 28.4 28.7
Not reported 0.5 0.1 1.9 0.5 0.9
Annual household income Low 29.1 38.5 19.6 30.7 28.3
Moderate 26.7 26.8 33.9 22.1 28.2
High 37.8 34.1 41.0 41.8 38.7
Not reported 6.4 0.6 5.5 5.4 4.8
Smoking Status Daily smoker 76.2 69.6 79.6 80.0 76.6
Recent ex-smoker 23.8 30.5 20.4 20.0 23.4
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for smoking cessation.14 National tracking data in England have 
shown that the increased use of NVPs was positively associated 
with a reduction in smoking.38,39 In contrast, Australian smokers 
were less likely to use NVPs for their LQA relative to the other 
countries. This could be because NVPs are effectively prohibited 
as they are classified as poison under Australian law; 40 thus, it is 
illegal to possess nicotine without a valid prescription. In general, 
Australian public health authorities have taken a “precautionary 
approach” and have mostly advised against their use, even for 
smoking cessation,17,40 albeit with some recent exceptions, where 
some Australian medical organizations have recognized they may 
have the potential to help some smokers quit.40 In the US, since 
2016, the Food and Drug Administration (FDA) has regulated 
NVPs as tobacco products.41 Many US-based public health organ-
izations have not supported the use of NVPs for smoking cessation, 
often citing insufficient evidence that e-cigarettes can help smokers 
quit, the unknown health harms of long-term/regular use, and use 
by nonsmokers (particularly by youth).42,43 Additionally, the 2019 
Table 2. Prevalence of Quit Aids Used at Last/Current Quit Smoking Attempt
n, yes
Weighted %N = 3614






Quitline service 166 2.5
Stop smoking service/counseling 193 3.1
Doctor 169 2.8
Mobile apps 208 4.6
Cessation website 417 8.5
Pamphlets/brochures 235 4.0
Heated tobacco product 101 1.2
Smokeless tobacco 64 1.1
Other type of support not listed above 61 1.8
Cessation Aid Categories*
Any type of OPT (varenicline/ bupropion/cytisine) 569 12.0
Any type of pharmacotherapy (NRT/OPT) 1593 38.4
Any use of NRT and/or or NVP 2112 49.9
Any use of NRT, OPT, and/or NVP 2364 57.2
Any type of (noncombustible) tobacco (HTP/smokeless) 154 1.7
Any type of services 425 7.8
Any type of other support 723 16.5
Exclusive Use of Pharmacotherapy, NVP, or Non-Combustible Tobacco
Used pharmacotherapy (NRT/OPT) only 654 17.4
Used pharmacotherapy/NVP/tobacco (noncombustible) only 1198 33.0
Any form of Combination of Aids
Any pharmacotherapy, NVP, tobacco, cessation services, and support combination 1218 25.0
Exclusive Use VS. Combination of Aids
NVP only 530 13.6
NRT only 450 12.2
OPT only 204 5.5
Cessation services only 41 0.8
Other support only 149 4.6
Tobacco (noncombustible) only 14 0.0
NVP + NRT 237 4.6
NVP + OPT 77 1.3
NRT + OPT 53 0.8
NVP + NRT + OPT 36 0.3
NVP + services or support 193 3.5
NRT + services or support 164 4.7
Other combinations 458 9.3
No Aid at all (no pharmacotherapy /NVP/Tobacco/Cessation Services/Support) 1008 38.6
Data are weighted and adjusted for age, sex, country, respondent type, and smoking status.*Quit aids are not mutually exclusive. 
NVP: nicotine vaping product; NRT: nicotine replacement therapy; OPT: other pharmacological therapies: varenicline, bupropion, cytisine; Tobacco 
(noncombustible): HTP or smokeless; Cessation services: quitline, doctor, clinic/counseling; Other support: mobile apps, cessation website, pamphlets/brochures, 
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outbreak of severe pulmonary disease (EVALI) in the US was ini-
tially attributed to NVPs, which greatly elevated concerns about 
the safety of vaping products, leading to a flurry of regulations to 
restrict consumer access to NVPs. The EVALI outbreak was later 
discovered to be caused by vaping vitamin E acetate added to can-
nabis vaping liquids.42,44,45 Thus, as a result of the negative publi-
city, smokers may have been discouraged from using NVPs when 
they attempted to quit smoking. The Canadian government’s 2018 
Tobacco and Vaping Products Act,46 allowed NVPs to be regu-
lated and sold. While the Canadian government has not approved 
e-cigarettes to be used as a method of cessation, they have suggested 
that NVPs may help smokers quit,47 but the Canadian Medical 
Association has called for more research into the possible health 
benefits and consequences of NVPs and evidence for their effect-
iveness as a smoking cessation aid.48 However, the wide range of 
availability in Canada and more liberal regulations since 2018 may 
account for the higher rates of NVP use for cessation in Canada 
compared to Australia and the US.
Interestingly, while there were country differences in the use of 
NVPs and NRT, the proportion using nicotine products in either 
Figure 1. Any use of quit aids/assistance among respondents who self-reported using an aid at LQA, n = 2606. Data are weighted and adjusted for age, sex, 
country, respondent type, and smoking status. Quit aids are not mutually exclusive. NVP: Nicotine vaping product; NRT: Nicotine replacement therapy; OPT: 
Other pharmacological therapies: varenicline, bupropion, cytisine; Tobacco: heated tobacco product (HTP), smokeless (snus, chew dip); Cessation services: 
quitline, doctor, clinic/counseling; Other support: mobile apps, cessation website, pamphlets/brochures, books, acupuncture, laser therapy, hypnosis, support 
groups, social media, cognitive behavioral therapy, meditation/mindfulness, quit the campaign.
Figure 2. Prevalence of quit aids used at last quit attempt by country, N = 3614. Data are weighted and adjusted for age, sex, country, respondent type, and 
smoking status. Quit aids are not mutually exclusive. NVP: Nicotine vaping product; NRT: Nicotine replacement therapy; OPT: Other pharmacological therapies 
(varenicline, bupropion, cytisine); Cessation services: quitline, doctor, clinic/counseling; Other support: mobile apps, cessation website, pamphlets/brochures, 
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of these forms was strikingly similar across the four countries. This 
may suggest that nicotine substitution is important for smokers 
when trying to quit, but that the proportion of smokers using NVPs 
versus NRT may vary depending on the country’s regulatory stance 
on NVPs. This seems to be most evident for Australia and England, 
where NRT was more commonly used in Australia relative to NVPs, 
and in England, NVPs were more commonly used than NRT. The 
use of NVPs and NRT was more evenly distributed in Canada and 
the US, where NVPs are legal and regulated, but not encouraged as a 
primary aid for cessation. However, while we have presented a snap-
shot of what smokers are using for their most recent quit attempt, 
we cannot attribute this to country policies in the present study due 
to the cross-sectional design. It would be valuable for future research 
to investigate how changing policies, either by increasing or reducing 
access to alternative noncombustible tobacco and nicotine products, 
may affect smoking cessation practices and smoking behaviors.
This study has important strengths, in that we had a large 
sample of current daily smokers and recent ex-smokers from four 
high-income countries. However, there are some important limita-
tions to also consider. First, this study was cross-sectional, and there-
fore it cannot be used to demonstrate temporality or infer causality. 
Second, due to the sampling methods of ITC 4CV, the estimates 
reported in this study may not be representative of each country’s 
population. In particular, vapers were purposefully recruited for 
this survey, so our results may over-represent the use of NVPs for 
cessation, even though weighting was applied to correct for over-
sampling. However, our estimates do not appear to be much dif-
ferent from national data. For example, the national Toolkit Study 
in England found that at the latest period (2020), 30% of those who 
made a quit attempt in England used an NVP,9 and our study found 
that 37% reported doing so. Canadian national data showed that 
23.6% used an NVP to help them quit smoking in 2019,10 and our 
study found that 26.7% used an NVP at LQA. Third, we did not 
ask respondents if their NVP contained nicotine at their LQA; how-
ever, only 38 respondents reported that at the time of the survey, 
they did not vape with nicotine. Therefore, it is unknown whether 
these respondents used a non-nicotine vaping product for quitting, 
or instead used a nicotine-based e-liquid at the time of their LQA, 
and then down-titrated to no nicotine use over time. An alternative 
explanation for those using NVP with NRT and/or OPT is that some 
used a non-nicotine e-cigarette to help with the behavioral substi-
tution of smoking only. Finally, the retrospective measurements in 
this study relied on respondent recall, which may impact reports of 
assistance used during a quit attempt. It has been previously shown 
that some smokers have poor recall of cessation methods,6,49 and 
that recall of quit attempts decreases with increasing time since the 
quit attempt,49,50 and this differs between those who used medication 
compared to those who did not.49
Conclusion
Although we know from two decades of research that smoking ces-
sation aids increase the likelihood of successful quitting, particularly 
pharmacotherapy, we found that over one-third of respondents did 
not use any type of aid during their most recent (last) quit attempt. 
And while this proportion is lower than previous reports,1 it appears 
that many smokers are still trying to quit unassisted rather than util-
izing proven cessation medications and services. Among respondents 
who did use an aid, nicotine substitution in the form of NRT and/or 
NVPs was the most commonly reported form of assistance. In light 
of these findings, it remains imperative that healthcare providers 
proactively screen for smoking, as well as communicate to smokers 
that their chances of successful smoking cessation will be greatly 
increased if they use an effective aid, particularly government-
approved stop-smoking medications combined with behavioral 
support. Additionally, healthcare providers should be prepared to 
discuss the use of vaping products since many smokers have heard 
of them, and some may already be using NVPs to transition off cig-
arettes. Regardless of whatever quit methods patients may be using, 
or consider using, health professionals need to support their patients’ 
efforts to quit cigarette use as soon as possible. Providing the most 
recent and accurate information to smokers about the risks and 
benefits of different smoking cessation aids is important, and where 
Table 3. Country Differences of Quit Aids Used At LQA
Country comparison OR LCI UCI
NVP (n = 1392)
Australia vs. Canada 0.75 0.54 1.05
Australia vs. England 0.47 0.33 0.68
Australia vs. United States 0.97 0.67 1.40
Canada vs. England 0.63 0.48 0.82
Canada vs. United States 1.29 0.96 1.71
England vs. United States 2.05 1.48 2.84
NRT (n = 1195)
Australia vs. Canada 1.07 0.80 1.44
Australia vs. England 1.79 1.26 2.54
Australia vs. United States 1.26 0.90 1.75
Canada vs. England 1.67 1.27 2.20
Canada vs. United States 1.18 0.90 1.53
England vs. United States 0.70 0.51 0.97
OPT (n = 569)
Australia vs. Canada 1.33 0.91 1.94
Australia vs. England 1.49 0.94 2.38
Australia vs. United States 0.91 0.61 1.37
Canada vs. England 1.12 0.77 1.63
Canada vs. United States 0.69 0.50 0.94
England vs. United States 0.61 0.41 0.92
Cessation services (n = 425)
Australia vs. Canada 1.50 0.94 2.40
Australia vs. England 0.85 0.52 1.39
Australia vs. United States 1.94 1.16 3.27
Canada vs. England 0.57 0.39 0.82
Canada vs. United States 1.30 0.85 1.98
England vs. United States 2.29 1.49 3.53
Other support (n = 723)
Australia vs. Canada 0.95 0.65 1.38
Australia vs. England 0.95 0.62 1.44
Australia vs. United States 1.72 1.08 2.73
Canada vs. England 1.00 0.74 1.36
Canada vs. United States 1.81 1.25 2.63
England vs. United States 1.81 1.20 2.74
No aid (n = 1008)
Australia vs. Canada 0.93 0.69 1.25
Australia vs. England 0.98 0.69 1.38
Australia vs. United States 0.75 0.53 1.05
Canada vs. England 1.05 0.81 1.38
Canada vs. United States 0.81 0.62 1.06
England vs. United States 0.76 0.56 1.05
Data are weighted and adjusted for age, sex, country, respondent type, and 
smoking status. 
LQA, last quit attempt; NVP, nicotine vaping product; NRT, nicotine replace-
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evidence is lacking, that should be acknowledged so that they can 
make informed choices. Future research should examine the extent 
to which NVPs may be displacing pharmacotherapies (particularly 
NRT) as a cessation method, as well as to how NVPs are contrib-
uting to the expansion of quitting smoking, both of which may have 
important implications for guiding policies and estimating the im-
pact of NVPs on population-level cessation rates.
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